Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cartesian Therapeutics (RNAC) Asset Utilization Ratio (2016 - 2025)

Historic Asset Utilization Ratio for Cartesian Therapeutics (RNAC) over the last 10 years, with Q3 2025 value amounting to 0.0.

  • Cartesian Therapeutics' Asset Utilization Ratio fell 9760.02% to 0.0 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.0, marking a year-over-year decrease of 9760.02%. This contributed to the annual value of 0.11 for FY2024, which is 477.7% down from last year.
  • As of Q3 2025, Cartesian Therapeutics' Asset Utilization Ratio stood at 0.0, which was down 9760.02% from 0.0 recorded in Q2 2025.
  • Cartesian Therapeutics' Asset Utilization Ratio's 5-year high stood at 0.76 during Q2 2022, with a 5-year trough of 0.0 in Q2 2025.
  • For the 5-year period, Cartesian Therapeutics' Asset Utilization Ratio averaged around 0.31, with its median value being 0.26 (2021).
  • As far as peak fluctuations go, Cartesian Therapeutics' Asset Utilization Ratio surged by 44299.0% in 2021, and later plummeted by 9840.08% in 2025.
  • Over the past 5 years, Cartesian Therapeutics' Asset Utilization Ratio (Quarter) stood at 0.52 in 2021, then increased by 23.74% to 0.64 in 2022, then tumbled by 80.35% to 0.13 in 2023, then tumbled by 30.91% to 0.09 in 2024, then plummeted by 96.72% to 0.0 in 2025.
  • Its Asset Utilization Ratio stands at 0.0 for Q3 2025, versus 0.0 for Q2 2025 and 0.08 for Q1 2025.